Rubiarbonone C inhibits platelet-derived growth factor-induced proliferation and migration of vascular smooth muscle cells through the focal adhesion kinase, MAPK and STAT3 Tyr705 signalling pathways.

Hyun-Soo ParkKhong Trong QuanJoo-Hui HanSang-Hyuk JungDo-Hyung LeeEunji JoTae-Wan LimKyung-Sun HeoMinKyun NaChang-Seon Myung

Published in: British journal of pharmacology (2017)

These findings suggest that rubiarbonone C inhibits the proliferation and migration of VSMCs by inhibiting the FAK, MAPK and STAT3 signalling pathways. Therefore, rubiarbonone C could be a good candidate for the treatment of cardiovascular disease.

Keyphrases

vascular smooth muscle cells
growth factor
signaling pathway
cardiovascular disease
angiotensin ii
oxidative stress
cell proliferation
pi k akt
diabetic rats
high glucose
cell migration
type diabetes
drug induced
biofilm formation
protein kinase
metabolic syndrome
cardiovascular risk factors